Gilead Sciences and Tempus AI have announced an expanded, multi-year collaboration aimed at deploying artificial intelligence and real-world data at scale across Gilead’s oncology pipeline. The agreement, announced today, represents a significant deepening of a relationship that has already shaped how Gilead approaches cancer drug development, and marks one of the most comprehensive AI-data partnerships in oncology to date.
Tempus AI made the announcement on LinkedIn earlier today:
Today we announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline.
“We are so excited to have entered into a strategic collaboration with Gilead whereby our multimodal data and AI-powered insights will support Gilead’s oncology pipeline. This work further expands our network of collaborators—including AZ, GSK, BMS, and Merck—who utilize Tempus’ clinical and genomic insights to drive innovation in oncology and beyond.” – Eric Lefkofsky, Tempus Founder and CEO.
Tempus AI/LinkedIn
From Selective Access to Enterprise-Wide Integration
To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence. The expanded agreement takes that relationship to a new level.
The new agreement provides Gilead with enterprise-wide access to Tempus’ AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services. Where Gilead previously accessed Tempus capabilities on a program-by-program basis, the expanded structure integrates Tempus intelligence across the entire oncology organization, a fundamentally different operational model.
Ryan Fukushima, CEO of Data & Apps at Tempus AI, offered a candid take on what separates this announcement from the typical pharma-tech partnership on LinkedIn:
Most partnerships announce a beginning but I’m most proud of our expansions.
It demonstrates an expanded vote of confidence, building on our existing work and, most importantly, supporting new options for patients.
Today, Tempus AI announced an expanded, multi-year collaboration with Gilead Sciences including enterprise-wide access to the Lens AI platform, broader datasets across multiple indications, and dedicated analytical services embedded into their R&D engine.
Anyone can announce a partnership. The harder thing is earning the right to do more and when a collaborator comes back and says “we want more.” More data. More modalities. More embedded into how we work.
Gilead has already been building on Tempus’ multimodal library across trial design, indication selection, biomarker strategy, health outcomes, and real world evidence generation. Teams are turning that data into insights that move drugs forward and ultimately improve the lives of cancer patients. This expansion isn’t a new bet, it’s a raised one.
In drug development, the field is full of promising pilots and headline collaborations. The signal is when real-world data is already woven into how a team works and they decide to go broader, not just deeper.
We we’re soley focused on creating valuable insights. We utilize great people, products and processes to build an intelligence engine that can enhance treatment options for patients.
Congrats to the Tempus and Gilead teams. Excited for what’s ahead.
Ryan Fukushima/Tempus AI
The expanded collaboration aims to combine Gilead’s scientific expertise with Tempus’ real-world data in oncology to inform clinical decision-making. Ryan Fukushima, CEO of Tempus Data & Apps, said the multimodal data library will provide the Gilead team with AI-driven insights for its research and development efforts.
The Data Infrastructure Behind the Deal
Tempus is not a conventional data vendor. The company operates a technology platform that applies artificial intelligence to precision medicine, maintaining what it describes as one of the world’s largest libraries of multimodal healthcare data. The company’s oncology dataset has been expanded to include approximately 3 million genomic sequences from patients undergoing hereditary cancer testing, while its radiology repository spans approximately 1.9 billion images across cardiology, pulmonology, and oncology.
That breadth of multimodal data, genomic, clinical, imaging, outcomes, is precisely what makes Tempus a compelling partner for a pharma organization trying to make smarter, faster decisions across an expansive pipeline. For Gilead, which is building oncology capabilities in ADCs, cell therapy, small molecules, and T-cell engagers simultaneously, the ability to pull AI-driven signal across modalities and indications is operationally transformative.
Patrick Loerch, SVP of Clinical Data Science at Gilead, framed the deal in terms of patient centricity:
We are excited to announce this expanded partnership with Tempus that reflects our shared priority of putting patients at the heart of innovation.
Patrick Loerch/LinkedIn
Financial Terms and Strategic Significance
The financial terms of the expanded agreement were not disclosed. That is not unusual for data and analytics partnerships of this nature, where value is measured in pipeline velocity and decision quality rather than discrete transactional milestones.
What is notable is the timing. Gilead is in the midst of its most aggressive oncology expansion in company history, three acquisitions in the first quarter of 2026 alone, totaling more than $15 billion in committed capital. Deploying enterprise AI infrastructure at this moment is not incidental: it is the connective tissue that allows a rapidly expanding portfolio to be intelligently managed. Real-world evidence informs indication selection for new assets; biomarker analytics shapes trial design; outcomes data feeds competitive intelligence. At scale, these capabilities are as strategically important as the pipeline assets themselves.
A New Standard for Pharma-AI Collaboration
The Gilead-Tempus expansion reflects a maturing model for how large pharmaceutical companies are integrating AI, not as a discrete tool for single programs, but as an enterprise capability embedded across the R&D organization. As oncology pipelines grow more complex and the cost of late-stage failure continues to rise, access to high-quality, AI-interpretable real-world data is increasingly a source of competitive advantage.
For Tempus, landing enterprise-wide access with a company of Gilead’s scale and oncology ambition validates its positioning as the data infrastructure layer for next-generation cancer drug development.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada